A new non-pharmacological vacuum therapy for female sexual dysfunction

Although Female Sexual Dysfunction (FSD) affects 40% of American women, the re is no FDA-approved pharmaceutical tberapy. no EROS-CTD (TM) (Clitoral Th erapy Device, UroMetrics, Inc., St. Paul, AIN) treatment is the first FDA c leared-to-market therapy for FSD. Clitoral engorgement is believed to play an important role in female sexual arousal and overall sexual satisfaction. The EROS-CTD is a small, battery-powered device designed to enhance clitor al engorgement, increase blood flow to the clitoris, and ultimately improve arousal in women with FSD. The objective of this study tvas to assess The effectiveness of the EROS-CTD on sexual arousal (genital sensation, vaginal lubrication, ability to reach orgasm, and sexual satisfaction) in normal v olunteers and women with FSD.